论文部分内容阅读
目的:评价CDP+Vp_(16)方案治疗非霍奇金淋巴瘤(NHL)的疗效和毒性。方法:1993年7月～1998年6月应用COP+Vp_(16)方案(环磷酰胺、长春新碱、强的松、足叶乙甙)和CHOP方案(环磷酰胺、阿霉素/表阿霉素、长春新碱、强的松)随机治疗58例NHL,每组29例,疗效和毒性用卡方检验。结果:COP+Vp_(16)组完全缓解率62.1％(18/29),总缓解率68.9％(20/29);CHOP组完全缓解率48.3％(14/29),总缓解率62.1％(18/29),两组差异均无显著性(P>0.05);两组毒性也无显著性差异(P>0.05)。结论:COP+Vp_(16)方案的近期疗效可达到CHOP方案水平,在长期化疗中,两方案可交替使用,其远期疗效有待进一步研究。两方案在心脏毒性方面无显著性差异(P>0.05),提示COP+Vp_(16)对心脏有一定毒性,临床用药时应密切观察。
OBJECTIVE: To evaluate the efficacy and toxicity of the CDP+Vp_(16) regimen in the treatment of non-Hodgkin’s lymphoma (NHL). METHODS: From July 1993 to June 1998, the COP+Vp_(16) regimen (cyclophosphamide, vincristine, prednisone, and etoposide) and CHOP regimen (cyclophosphamide, doxorubicin/tablet) were used. Doxorubicin, vincristine, and prednisone were used to randomly treat 58 cases of NHL, 29 cases in each group. The efficacy and toxicity were tested by Chi-square test. Results: The complete remission rate was 62.1% (18/29) in the COP+Vp_(16) group, and the total remission rate was 68.9% (20/29); the complete remission rate in the CHOP group was 48.3% (14/29), and the total remission rate was 62.1% ( 18/29), there was no significant difference between the two groups (P>0.05); there was no significant difference between the two groups (P>0.05). Conclusion: The short-term efficacy of COP+Vp_(16) regimen can reach the level of CHOP regimen. In long-term chemotherapy, both regimens can be used interchangeably, and its long-term efficacy needs further study. There was no significant difference in cardiotoxicity between the two regimens (P>0.05), suggesting that COP+Vp_(16) has certain toxicity to the heart and should be closely observed during clinical drug use.